Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment

On December 4, Leerink expert David Risinger maintained an Outperform standing connected Bristol-Myers Squibb Company (NYSE:BMY). The expert highlighted that the institution plans to enroll much patients successful the ADEPT-2 survey and sees this arsenic a affirmative development. He noted that the Data Monitoring Committee besides suggested expanding registration successful Cobenfy’s ADEPT-2 proceedings successful Alzheimer’s illness psychosis patients.

Bristol-Myers Squibb Company (NYSE:BMY) has been encountering immoderate difficulties implicit the past fewer years owed to patent cliffs. However, the institution has a batch of products successful the pipeline, particularly successful the oncology market. In the 3rd 4th of 2025, BMY’s maturation portfolio gross grew by 18% to $6.9 billion, chiefly driven by its immuno-oncology portfolio. Its full revenues for the 4th came successful astatine $12.2 billion, up 3% from the aforesaid play past year.

Though Bristol-Myers Squibb Company (NYSE:BMY)’s outlook is precise promising, the institution mightiness beryllium struggling connected the dividend front. Is payout ratio is astir 80%, which isn’t encouraging quality for income investors. However, the company’s trailing twelve-month escaped currency travel of $15.3 cardinal was capable to screen dividend payments worthy $5 billion. BMY has besides raised its payouts for 16 consecutive years.

Bristol-Myers Squibb Company (NYSE:BMY) is simply a planetary biopharmaceutical institution that discovers and manufactures medicines and treatments for superior illnesses.

While we admit the imaginable of BMY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio and 15 Dividend Stocks That Outperform the S&P 500.

Disclosure: None.